Dealmaking Roundup March 2007
Executive Summary
Summary of recent device mergers and acquisitions, alliances, and financings.
You may also be interested in...
CV Sciences Reboots PlusCBD Brand While Counting On New Immunity Products During Flu Season
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Finance Watch: Have Investors Reached IPO Fatigue?
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Expediting The Expedited: How Rolling CMC Review Process Is Working For COVID-19 Vaccines
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: